首页 | 本学科首页   官方微博 | 高级检索  
     

磷脂酰肌醇蛋白聚糖- 3在乙肝肝硬化患者中鉴别小肝癌的价值
引用本文:徐震,朱善军,马春芳,郝天波,张肖,陆斐斐,吴继华. 磷脂酰肌醇蛋白聚糖- 3在乙肝肝硬化患者中鉴别小肝癌的价值[J]. 现代预防医学, 2018, 0(10): 1900-1903
作者姓名:徐震  朱善军  马春芳  郝天波  张肖  陆斐斐  吴继华
作者单位:南通大学附属苏州市吴江区第一人民医院检验科,江苏 南通 215200
摘    要:目的 探究磷脂酰肌醇蛋白聚糖-3(GPC-3)在乙肝肝硬化患者中鉴别小肝癌(SHCC)的价值。方法 选取某院住院治疗的符合要求的乙肝肝硬化患者及乙肝肝硬化合并SHCC患者作为研究对象,分别定义为肝硬化组和SHCC组。收集2组患者的一般资料并利用单多因素分析筛选出导致肝硬化合并小肝癌的危险因素。利用ROC曲线分析各指标鉴别乙肝肝硬化合并SHCC的潜在诊断效能。 结果 本研究共纳入103例患者。其中肝硬化组共67例, SHCC组共36例。SHCC组患者的总胆红素、MRI检查、血清AFP、血清GPC - 3等指标显著高于肝硬化组,差异均有统计学意义(P<0.05)。其中MRI检查、血清AFP和血清GPC - 3是乙肝肝硬化合并SHCC的影响因素(P<0.05)。受试者的血清GPC-3和血清AFP呈正相关(r = 0.222,P<0.05)。血清AFP和血清GPC-3鉴别乙肝肝硬化合并HCC的AUC为0.723和0.884,其敏感度为69.44%和66.67%,特异度为61.19%和100%;二者联合诊断鉴别乙肝肝硬化合并HCC的AUC最高(0.927)。结论 GPC-3在乙肝肝硬化患者中鉴别小肝癌时具有一定的价值,可作为诊断乙肝肝硬化合并小肝癌的指标之一。

关 键 词:磷脂酰肌醇蛋白聚糖-3  乙肝肝硬化  小肝癌  血清肿瘤标志物

Value of serum glypican-3 in the differentiation of small hepatocellular carcinoma from hepatitis-B virus cirrhosis
XU Zhen,ZHU Shan-jun,MA Chun-fang,HAO Tian-bo,ZHANG Xiao,LU Fei-fei,WU Ji-hua. Value of serum glypican-3 in the differentiation of small hepatocellular carcinoma from hepatitis-B virus cirrhosis[J]. Modern Preventive Medicine, 2018, 0(10): 1900-1903
Authors:XU Zhen  ZHU Shan-jun  MA Chun-fang  HAO Tian-bo  ZHANG Xiao  LU Fei-fei  WU Ji-hua
Affiliation:Department of Laboratory, Nantong University Affiliated Suzhou Wujiang District First People 's Hospital, Nantong, Jiangsu 215200, China
Abstract:Objective To explore the value of serum glypican-3 in the differentiation of small hepatocellular carcinoma(SHCC) from hepatitis-B virus cirrhosis. Methods The patients with hepatitis-B cirrhosis and hepatitis-B cirrhosis with SHCC in our hospital were involved and divided into the cirrhosis group and the SHCC group. General data from both groups were recorded and single & multi-factor analyses were used to screen risk factors for hepatitis-B cirrhosis with SHCC. ROC curve analysis was used to explore the potential diagnostic efficacy of hepatitis-B cirrhosis with SHCC. Results A total of 103 patients were enrolled in this study, including 67 patients in the cirrhosis group and 36 patients in the SHCC group. The total bilirubin, MRI examination, serum AFP and serum GPC-3 in the SHCC group were significantly higher than that in cirrhosis group,differences were statistically significant(P<0.05). Among them, MRI examination, serum AFP and serum GPC-3were the factors for hepatitis-B cirrhosis combined with SHCC(P<0.05). Serum GPC-3 was positively correlated with serum AFP(r=0.222, P<0.05). The AUC serum AFP and serum GPC-3 in the differential diagnosis of hepatitis-B cirrhosis combined with SHCC were 0.723 and 0.884, and the sensitivity were 69.44% and 66.67%, the specificity was 61.19% and 100%. The AUC of combined diagnosis was highest (0.927). Conclusion GPC-3 is valuable in the identification of hepatitis-B cirrhosis combined with SHCC. It can be used as one of the indicators in the diagnosis of hepatitis-B cirrhosis combined with SHCC.
Keywords:Glypican-3  Hepatitis-B cirrhosis  Small hepatocellular carcinoma  Serum tumor markers
本文献已被 CNKI 等数据库收录!
点击此处可从《现代预防医学》浏览原始摘要信息
点击此处可从《现代预防医学》下载全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号